We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 371

Court finds patent indefiniteness in unobtrusive claims

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 15 2014

In Interval Licensing LLC v. AOL, Inc., the Federal Circuit applied the test for patent indefiniteness set forth in the recent Supreme Court decision

Federal Circuit frames test for patent-eligibility

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 8 2014

Personalized medicine relies on diagnostics to analyze a patient for individualized therapy and for monitoring a patient's health status. Some

Australia upholds patent eligibility of isolated DNA

  • Foley & Lardner LLP
  • -
  • Australia
  • -
  • September 8 2014

The Full Federal Court of Australia affirmed that isolated nucleic acids, i.e. whether it be DNA or RNA, are patentable subject matter in Australia

Federal Circuit finds Apotex ANDAs do not infringe Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 2 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Federal Circuit upholds validity of Lysteda patents

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 28 2014

In two decisions issued under the same name (Ferring B.V. V. Watson Laboratories, Inc.), the Federal Circuit upheld the validity of the Orange

Humira patent invalid for obviousness type double patenting

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering

Will the USPTO respond to public feedback of its eligibility guidance?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

Periodically, the USPTO holds open meetings with the public to discuss its thinking on current topics relating to the patent procurement process

Are permanent injunctions in patent cases back in style?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 21 2014

Two recent district court decisions out of the District of Delaware have again placed the spotlight on permanent injunctions in patent cases. Prior

Federal Circuit upholds inequitable conduct defense against Apotex patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 18 2014

In Apotex Inc. v. UCB, Inc., the Federal Circuit upheld the district court's finding that Apotex's patent is unenforceable due to inequitable conduct

NPEs continue to play large role in patent litigation

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 17 2014

The annual patent litigation study recently released by PricewaterhouseCoopers LLP (PwC) sets forth some interesting trends in patent litigation